Kornimate/medical-research-clean huggingface dataset:
preventing childhood asthma using prophylactic house dust mite allergen immunotherapy

Conditions: Asthma; Allergy

Summary: to establish efficacy and safety of hdm sublingual immunotherapy (hdm-slit) by comparing odactra and placebo, when given sublingually for 3 years to high risk infants aged between 6 to 12 months at enrollment in preventing the development of asthma, assessed 1.5 years after discontinuation of treatment.

aim to prevent the development of asthma in children by intervening at a time when the developing system in still amenable to immune modulation, by using the only therapy that has proven ability to change the natural history of allergic diseases and induce clinical remission. we hypothesize that three years of hdm immunotherapy in high-risk infants will prevent the development of asthma assessed over a period of 1.5 years after discontinuation of treatment and hdm immunotherapy will result in (a) a significant reduction in the number and pathogenic features of hdm-reactive th2 cells, and (b) an increase in the numbers of hdm-reactive th and treg cells expressing the interferon-response signature. the study is a randomized (1:1), double blinded, placebo controlled, parallel arms, multi-site, phase ii study with a 3 year treatment phase and further 1.5 year follow-up phase. the study duration for each participant is 4.5 years. overall study duration is 84 months (7 years); which include 9 months preparation and regulatory approvals, 15 months accrual, 36 months treatment and 18 months follow-up observation period.

Eligibility criteria:
inclusion criteria: 1. aged 6 to 12 months of age 2. history of physician diagnosed atopic dermatitis or 3. allergen sensitization or 4. family history of asthma or allergy exclusion criteria: 1. evidence of sensitization to house dust mite (spt ≥3 mm or sige (\> 0.35 ku/l) 2. prematurity (\<37 weeks) 3. failure to thrive 4. need for oxygen for more than 5 days in the neonatal period 5. history of intubation or mechanical ventilation
measuring quality of decisions about treatment of menopausal symptoms

Conditions: Menopause

Summary: the purpose of this randomized controlled trial is to examine the impact of a patient decision aid on the quality of decisions about managing symptoms of menopause. in particular, we will examine whether the decision aid increases knowledge about menopause/managing menopause symptoms and concordance between goals and treatment choices.


Eligibility criteria:
inclusion criteria: * female, aged 40-60 * talked with health care provider about ways to manage menopause within last year or seriously considered taking medicine or supplement to manage menopause within the last year exclusion criteria: * prior diagnosis of breast cancer * surgical or medically induced menopause (ovaries removed)

Keywords: menopause decision making decision aids decision quality instrument
a phase i/ii study of he3235 in patients with prostate cancer

Conditions: Prostate Cancer

Summary: this is a phase i/ii, open-label, dose escalation study of he3235 administered orally to patients with advanced prostate cancer who have failed hormone therapy and at least one taxane based chemotherapy regimen.


Eligibility criteria:
main inclusion criteria: * patient is male and at least 18 years of age, at the time of screening; * patient has metastatic disease (any t, any n, m1); * patient has failed at least 1 taxane regimen; or patient has symptomatic or asymptomatic crpc and is chemotherapy-naïve * patient has histologically or cytologically confirmed adenocarcinoma of the prostate; * patient has progression of disease despite adequate hormone therapy, demonstrated by one of the following: * psa level of at least 2 ng/ml that has risen on at least 2 successive occasions, at least 1 week apart. * evaluable disease progression by modified recist (response evaluation criteria in solid tumors) criteria; * progression of metastatic bone disease on bone scan with \> 2 new lesions * patient has ecog (eastern cooperative oncology group) performance status of 0-2; main exclusion criteria: * patient has symptomatic parenchymal brain metastases or active epidural disease requiring whole-brain irradiation treated epidural disease is allowed * patient has active infection; * patient having a history of clinically significant cardiovascular disease (such as chf), clinically significant hepatic, respiratory or renal abnormalities; * patient who has any clinically significant abnormalities in laboratory results at screening * patient who has a history of clinically significant neurological or psychiatric condition; additional criteria are applicable to expansion cohorts.

Keywords: prostate cancer he3235 apoptone
chinese medicinal treatment on mild hand, foot, and mouth disease: multicenter, prospective, randomized double-blind, placebo-controlled study

Conditions: Hand, Foot and Mouth Disease

Summary: the study is aimed to evaluate the effectiveness and safety of jinlianqingre effervescent tablets, a traditional chinese medicine (tcm), in the treatment of uncomplicated hand, foot, and mouth disease (hfmd).

by adopting a multicenter, prospective, randomized double-blind, placebo-controlled, this study is aimed to evaluate the effectiveness, safety of a traditional chinese medicine, jinlianqingre effervescent tablets, for treatment uncomplicated hfmd, and to provide scientific evidence for the construction of tcm methods in treating hfmd.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild hand-foot-mouth disease patients according to hand-foot-mouth disease treatment guidelines 2010 issued by china's ministry of health; * within 48 hours of onset of fever and rash symptom. * age of 1-13 years. * documented body temperature 37.4 °c-39.0°c * patients or their guardians agree to participate in this study and signed the informed consent form. exclusion criteria: * complicated with other serious diseases such as chronic hepatitis,chronic diarrhea disease,chronic diarrhea, congenital heart disease, acute or chronic nephritis and blood diseases. * with history of allergies on traditional chinese medicine. * attending other clinical studies on hfmd after diagnosed.

Keywords: hand, foot and mouth disease medicine, chinese traditional enterovirus fever
advantage of tramadol in local analgesia post-sternotomy

Conditions: Heart Surgery Via Sternotomy; Post-operative Analgesia

Summary: sternotomy, the reference approach for heart surgery, may induce profound and intense post-operative pain. one method of analgesia used is patient-controlled intravenous morphine. the analgesic efficacy of continuous wound infiltration at the sternum following heart surgery has been demonstrated. the analgesic catheter placed near the sternotomy wound reduces the consumption of morphine. the aim of this study is to determine whether a bolus of tramadol associated with the continuous administration of levobupivacaine via the wound catheter could potentiate the local anaesthetic effects, thus leading to a decreased consumption of postoperative intravenous morphine, and a decrease in morphine-related side effects.


Eligibility criteria:
inclusion criteria: * persons who have provided written consent * patients over 18 years old * patients undergoing heart surgery via sternotomy: aortic valve surgery, mitral valve surgery, tricuspid valve surgery, atrial myxoma, coronary artery bypass graft, aorta surgery * patients undergoing emergency or scheduled surgery exclusion criteria: * adults under guardianship * persons without national health insurance cover * pregnant or breast-feeding women * patients already included in the study once * patients with aortic dissection * patients with mediastinitis or sternal nonunion * patients undergoing heart surgery for the second or more time * patients with local infection or generalized bacteraemia-type infection * patients with hypersensitivity to local anaesthetics or to tramadol or to opiates or to one of the excipients present in the products used * patients with hypersensitivity to paracetamol or to paracetamol hydrochloride (prodrug of paracetamol) * patients on antidepressants, gabapentin, pregabalin, neuroleptics * patients with a history of convulsions or epilepsy * patients with preoperative cognitive dysfunction * patients with intracranial hypertension * chronic use of morphines or high-dose steroid or non-steroid anti-inflammatory agents * patients with acute or chronic kidney failure (creatininemia \> 170 µmol/l) * patients with liver failure or porphyria * patients under 17 years old * patients with severe respiratory failure * patients treated with a non-selective maoi (iproniazid), a selective maoi a (moclobemid, toloxatone), selective mao-b inhibitor (selegiline) or linezolid (zyvoxid®) * patients with acute intoxication or an overdose of products that depress the central nervous system (alcohol, hypnotics, other analgesics...) * patients with severe hypotension
ultra-protective pulmonary ventilation supported by low flow ecco2r for severe ards

Conditions: Respiratory Distress Syndrome, Adult

Summary: this study evaluates the use of ultra-protective ventilation, where very low ventilation volumes are used, in patients with severe acute respiratory distress syndrome (ards) meeting criteria to nurse in the prone position. half the patients will receive ultra-protective ventilation support by extracorporeal carbon dioxide removal, while the other half will receive conventional lung protective ventilation.

current best practices for management of severe ards include lung protective ventilation and nursing in the prone position. however, the best lung protective strategy is not currently established and using smaller ventilation volumes than standard lung protective ventilation suggest lung recovery is improved. application of smaller ventilation volumes requires extracorporeal carbon dioxide removal, using a device similar to a dialysis to remove carbon dioxide directly from the blood. one such device in the prismalung, it removes blood through a catheter, much like a dialysis catheter, pumps it through a gas exchange cartridge which removes carbon dioxide. the gas exchange cartridge functions in a similar way to a dialysis filter, except it allow gases to pass through, unlike dialysis filters which allow passage of fluid and small molecules.

Eligibility criteria:
inclusion criteria: * admitted to micu with respiratory failure and intubated * ards criteria per berlin definition * pao2:fio2 ratio ≤ 200 mmhg for \> 6 hours with fio2 ≥0.5 * expected to require mechanical ventilation for \>48 hours * reversible disease exclusion criteria: * anticoagulation contraindicated * proven hit * unable to obtain central venous access * refractory hypoxia (pao2:fio2 ≤80 after recruitment and proning) or other indication for ecmo * home oxygen use * severe copd * interstitial lung disease * \> 7 days of mechanical ventilation * immunocompromised patient (bone marrow, untreated hiv, pjp) * advanced malignancy with life expectancy ≤ 6months
effect of activity modification and exercises in young adolescents with osgood schlatter disease.

Conditions: Osgood Schlatter Disease

Summary: the purpose of this study is to investigate the effect of activity modification, exercises and a gradual return to sport in adolescents (age 10-14) with osgood schlatter disease. the primary outcome is self-reported recovery on a 7-point likert scale at 3 months. secondary endpoints include 4 and 8 weeks and 6 and 12 months after inclusion into the project. the adolescents will be recruited from primary schools, general practitioners and through online advertising on facebook.


Eligibility criteria:
inclusion criteria: * 10-14 years of age * pain at tuberositas patellae during two or more of the following activities: sitting with a bent knee, squatting, running, jumping or stair ambulation * pain during palpation of tuberositas patellae * knee pain for 6 weeks or more exclusion criteria: * other knee conditions that may manifest as anterior knee pain (patellofemoral pain, iliotibial band syndrome, sinding-larson-johanson disease). * previous surgery * pain from the hip or back that interferes with activities of daily living. * habitual patella luxations * clinical suspicion of meniscal lesion
177lu-labeled ny108 spect imaging in patients

Conditions: Prostate Cancer

Summary: this is a single arm study to evaluate the safety and biodistribution of 177lu-labeled ny108 (177lu-ny108) spect imaging in patients.


Eligibility criteria:
inclusion criteria: 1. patients voluntarily signed informed consent; 2. age 18-75, male; 3. clinical diagnosis of prostate cancer with diagnostic criteria referencing biopsy and at least one metastasis; 4. patients must be 68ga-ny108 positron emission tomography (pet)/computed tomography (ct) scan positive; 5. patients must have received at least one naad (such as enzalutamide and/or abiraterone) and at least one paclitaxel regimen; 6. progressive metastatic destructive resistant prostate cancer as determined by pcwg3 criteria; 7. an ecog score of 0-2 exclusion criteria: 1. recovery from major trauma (including surgery) within 4 weeks prior to study treatment; 2. patients with severe systemic or localized infections or other serious coexisting diseases; 3. patients with abnormal immune function or who have recently used immunosuppressive or booster agents including various vaccines, etc; 4. patients with autoimmune diseases, including rheumatoid, etc; 5. inadequately controlled arrhythmias, including atrial fibrillation: 6. cardiac insufficiency (new york heart association (nyha) work class criteria); 7. uncontrolled hypertension; 8. patients with a history of allergy or hypersensitivity to any component of the imaging agent, including antibodies; 9. subjects positive for syphilis, hbv, hcv, fiiv; 10. subjects of childbearing age who are unable to use effective contraceptive devices: 11. patients with a history of mental illness or related medical conditions; 12. patients who are unable or unavailable for spect/ct scanning; 13. other subjects who, in the opinion of the investigator, are not suitable for enrollment.
dose-finding study of oral ibrexafungep (scy-078) vs. oral fluconazole in subjects with acute vulvovaginal candidiasis

Conditions: Candida Vulvovaginitis

Summary: this is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral scy-078 versus oral fluconazole in adult female subjects 18 years and older with moderate to severe acute vulvovaginal candidiasis (avvc). approximately 180 eligible subjects (30 subjects per treatment group) will be enrolled and randomized into the study.

this is a phase 2, multicenter, randomized, double-blind, double-dummy, active-controlled, dose-ranging study of female subjects with moderate to severe acute vulvovaginal candidiasis. subjects will be randomized to either the investigational arm (scy-078) with 5 different dose regiments ranging from 1 to 3 days of treatment or to the active-control arm (fluconazole) for 1 day of treatment. after randomization subjects may be seen on study day 3 (on site visit for pk subjects) , day 10 (±2,) and day 25 (+4).

Eligibility criteria:
key inclusion criteria: 1. subject is a female of at least 18 years of age 2. subject has a diagnosis of symptomatic avvc at baseline including a positive microscopic examination with 10% koh in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal ph (≤4.5) key exclusion criteria: 1. subject has any vaginal condition other than avvc that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection) 2. need for systemic and/or topical (vaginal) antifungal treatment, including prescription or over-the-counter products during the study and treatment for vvc 28 days prior to randomization 3. subject is actively menstruating at the time of the baseline visit. 4. subject has uncontrolled diabetes mellitus. 5. subject has a vaginal sample with ph \>4.5. 6. subject has a history of or an active cervical/vaginal cancer.
the individualized stepwise treatment mode of adolescent idiopathic scoliosis

Conditions: Adolescent Scoliosis

Summary: based on the risk factors affecting adolescent scoliosis found in the previous social survey, this project adopts the paradigm based on transfer learning and semi-supervised learning, and uses mathematical methods such as multiple learning methods and transformer image classification algorithms to develop and verify the early warning model and stepped treatment model of adolescent scoliosis, and conducts cost-effect analysis.

this study intends to build a standard system for the prevention and treatment of scoliosis in adolescents, do a good job in school health education and prevention and control work in school, comprehensively strengthen the construction of the prevention and control system of spondylosis, improve the ability of professionals in medical institutions, and give full play to the role of home-school-medical in the prevention and control of abnormal spinal curvature in children firstly, relying on the investigation report, we independently develop the software platform and physical device for measuring, preventing and correcting scoliosis. secondly, we use a series of prevention and control advantages to change from passive to active. based on the internet and big data technology, we integrate western medicine data management and monitoring technology to establish the characteristics of the disease general disease information (personal history, family history, solar terms, climate and environment detection indicators, etc.) as one of the health management platform, the management platform set up health archives disease risk early warning health intervention and health promotion education follow-up management system management data quality control review data analysis and visualization 9 modules, respectively set up a management platform patient-side physician side and management background 3 parts through sampling investigation clinical research, break the medical school barriers, to build a personalized step treatment model for adolescent scoliosis.

Eligibility criteria:
inclusion criteria: 1. the diagnosis of moderate and mild ais, with a cobb angle measuring less than 45°; 2. the age range of 12 to 16 years old; 3. participants are required to have no history of mental illness, possess normal communication skills, and be proficient in reading and writing; 4. signed informed consent by the patient or their family. exclusion criteria: patients who fulfill any of the following conditions will be excluded a clear history of inducement, such as diseases caused by trauma, surgery, cognitive impairment, severe dysfunction of heart, liver, kidney and other organs, and malignant tumors, immune diseases and other malignant diseases.
the effect of hydration on postprandial metabolic responses

Conditions: Glycaemia

Summary: certain populations, such as industrial workers and endurance athletes are particularly susceptible to dehydration due to exposure to heat for long periods of time causing evaporative water loss via sweating. the physical and cognitive decrements associated with dehydration have been widely researched, however the effect of dehydration on metabolism is lesser known. as climate change is causing temperatures to rise, and metabolic diseases such as type 2 diabetes are more common, the effect of dehydration on metabolism, specifically glycemic response to meals, needs to be established for future recommendations in clinical, environmental and athletic settings. therefore, the aim of this study is to investigate the effect of acute exercise-induced dehydration on subsequent metabolic responses to feeding (i.e. glycaemia and insulinaemia).


Eligibility criteria:
inclusion criteria: * male or female * generally fit and healthy * participate in endurance or intermittent exercise at least 3 times a week or minimum of 150 minutes moderate intensity activity per week exclusion criteria: * \ 45 * any health condition that may affect study outcomes (e.g., endocrine/liver/renal/cardiovascular disease) * any morbidity that affects ability to cycle * smoker or vaper

Keywords: hydration dehydration hypohydration glycemia glycaemia glucose control
the impact of serial remote ischemic conditioning on dynamic cerebral autoregulation in healthy adults

Conditions: Remote Ischemic Conditioning

Summary: the purpose of this study is to determine the impact of serial remote ischemic conditioning on dynamic cerebral autoregulation and related hematology indexes in healthy adults.

remote ischemic conditioning(ric) is the phenomenon whereby brief cycles of ischemia and reperfusion, applied to a distant organ, provide protection to the target organ. dynamic cerebral autoregulation(dca), a mechanism to maintain the cerebral blood flow, has been proved to be critical for the occurrence,development and prognosis of ischemic neurovascular disease. in this study, we hypothesis that ric provides neuro-protection by means of improving dca.

Eligibility criteria:
inclusion criteria: * age from 18 to 50,both genders * willing to participate in follow-up visits exclusion criteria: * current or having a history of chronic physical diseases or mental diseases * suffering from infectious diseases in late one month * pregnant and lactating women# * smoking or drinking# * inability to cooperate sufficiently to complete the dca examination

Keywords: remote ischemic conditioning dynamic cerebral autoregulation
benefit of adding chemotherapy and/or modification of radiotherapy schedule for advance nasopharyngeal carcinoma (t3-4n0-1m0)

Conditions: Nasopharyngeal Neoplasms; Carcinoma, Squamous Cell

Summary: to test the therapeutic ratio of accelerated radiotherapy and/or chemotherapy on locally advanced nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: * undifferentiated or non-keratinizing carcinoma * tumor staged as t3-4 and n0-1 * no evidence of distant metastasis (m0) * performance status: 0-2 * marrow: wbc \>= 4 and platelet = 100 * renal: creatinine clearance = 60 * informed consent exclusion criteria: * who type i squamous cell carcinoma or adenocarcinoma * age \>= 70 * palliative intent or tumor extent mandating ap opposing facio-cervical fields * prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years * previous radiotherapy (except non-melanomatous skin cancers outside the intended rt treatment volume * previous chemotherapy * patient is pregnant or lactating

Keywords: nasopharyngeal carcinoma t3-4n0-1m0